TrialSignal
Clinical trial intelligence report
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00991562
Status
COMPLETED
Phase
PHASE1
Sponsor
ImmunoGen, Inc.
Executive brief
Investment-Ready Snapshot
The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00991562
Indication
Multiple Myeloma
Modality
small molecule
Target
IMGN901
Intervention
IMGN901
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.